eGFR <45 ml/min
structural and functional urogenital abnormalities, that predispose for urogenital infections
Investigational product use in the last 6 months
SGLT2 inhibitor, TZD, DPP4 inhibitor and GLP1 RA use within the past 6 months
DKA(Diabetic Ketoacidosis) or HHS(Hyperosmoloar Hyperglycaemic Syndrome) within the last 6 months
Pregnancy
Presence of major contraindications to magnetic resonance imaging (cardiac pacemakers, claustrophobia, foreign bodies and implanted medical devices with ferromagnetic properties).
Liver cirrhosis
Type 1 diabetes
Severe uncorrected insulin insufficiency
Significant alcohol intake
HIV infection
Use of Traditional Chinese Medication or alternative therapies
Coexisting causes of chronic liver disease - chronic viral hepatitis(B & C), autoimmune liver disease, hemochromatosis, Wilson's etc.
Use of medications associated with steatosis eg. Methotrexate, anticonvulsants, antiretroviral therapy etc.
h/o stroke
Steroid therapy
Endogenous Cushing's
Familial hypertriglyceridemia

NCT02964715_exc_T1
Measurement
eGFR
NCT02964715_exc_T2
Value
<45 ml/min
NCT02964715_exc_T3
Condition
urogenital abnormalities
NCT02964715_exc_T4
Qualifier
structural
NCT02964715_exc_T5
Qualifier
functional
NCT02964715_exc_T7
Scope
structural and functional
NCT02964715_exc_T8
Observation
predispose for urogenital infections
NCT02964715_exc_T9
Condition
urogenital infections
NCT02964715_exc_T10
Procedure
Investigational product use
NCT02964715_exc_T11
Temporal
in the last 6 months
NCT02964715_exc_T12
Drug
SGLT2 inhibitor
NCT02964715_exc_T13
Drug
TZD
NCT02964715_exc_T14
Drug
DPP4 inhibitor
NCT02964715_exc_T15
Drug
GLP1 RA
NCT02964715_exc_T16
Temporal
within the past 6 months
NCT02964715_exc_T17
Scope
SGLT2 inhibitor, TZD, DPP4 inhibitor and GLP1 RA
NCT02964715_exc_T18
Condition
DKA
NCT02964715_exc_T19
Condition
Diabetic Ketoacidosis
NCT02964715_exc_T20
Condition
HHS
NCT02964715_exc_T21
Condition
Hyperosmoloar Hyperglycaemic Syndrome
NCT02964715_exc_T22
Temporal
within the last 6 months
NCT02964715_exc_T23
Scope
DKA(Diabetic Ketoacidosis) or HHS(Hyperosmoloar Hyperglycaemic Syndrome)
NCT02964715_exc_T25
Procedure
magnetic resonance imaging
NCT02964715_exc_T26
Observation
major contraindications
NCT02964715_exc_T27
Device
cardiac pacemakers
NCT02964715_exc_T28
Condition
claustrophobia
NCT02964715_exc_T29
Observation
foreign bodies
NCT02964715_exc_T30
Device
implanted medical devices
NCT02964715_exc_T31
Qualifier
ferromagnetic properties
NCT02964715_exc_T32
Condition
Liver cirrhosis
NCT02964715_exc_T33
Condition
Type 1 diabetes
NCT02964715_exc_T34
Condition
insulin insufficiency
NCT02964715_exc_T35
Qualifier
uncorrected
NCT02964715_exc_T36
Qualifier
Severe
NCT02964715_exc_T37
Scope
Severe uncorrected
NCT02964715_exc_T38
Observation
alcohol intake
NCT02964715_exc_T39
Qualifier
Significant
NCT02964715_exc_T40
Condition
HIV infection
NCT02964715_exc_T41
Procedure
Traditional Chinese Medication
NCT02964715_exc_T42
Procedure
alternative therapies
NCT02964715_exc_T43
Condition
chronic liver disease
NCT02964715_exc_T44
Condition
 hepatitis(B & C), aut m
NCT02964715_exc_T45
Condition
 hepatitis(B & C), aut e
NCT02964715_exc_T47
Condition
autoimmune liver disease
NCT02964715_exc_T48
Condition
hemochromatosis
NCT02964715_exc_T49
Condition
Wilson's
NCT02964715_exc_T50
Scope
chronic viral hepatitis(B & C), autoimmune liver disease, hemochromatosis, Wilson's
NCT02964715_exc_T51
Drug
medications
NCT02964715_exc_T52
Condition
steatosis
NCT02964715_exc_T53
Drug
Methotrexate
NCT02964715_exc_T54
Drug
anticonvulsants
NCT02964715_exc_T55
Drug
antiretroviral therapy
NCT02964715_exc_T56
Scope
Methotrexate, anticonvulsants, antiretroviral therapy
NCT02964715_exc_T57
Condition
stroke
NCT02964715_exc_T58
Drug
Steroid therapy
NCT02964715_exc_T59
Condition
Cushing's
NCT02964715_exc_T60
Qualifier
Endogenous
NCT02964715_exc_T61
Condition
Familial hypertriglyceridemi